• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Factors associated with inpatient mortality during daunorubicin and cytarabine induction in adults with acute myeloid leukemia-a national inpatient sample analysis.

作者信息

Savani Saloni, Chennapragada Suma Sri, Ramphul Kamleshun, Dandwani Mehndi, Verma Renuka, Sanikommu Sailaja, Pagidipally Alekhya, Arti Fnu, Kumar Vijay, Sombans Shaheen, Ramphul Yogeshwaree, Mejias Stephanie G, Dhillon Balkiranjit Kaur, Lohana Petras, Sharma Shivani

机构信息

Willis Knighton Health System, Shreveport, LA, USA.

Louisiana State University Health Shreveport, Shreveport, LA, USA.

出版信息

Ann Hematol. 2024 Feb;103(2):663-665. doi: 10.1007/s00277-023-05505-x. Epub 2023 Oct 27.

DOI:10.1007/s00277-023-05505-x
PMID:37889285
Abstract
摘要

相似文献

1
Factors associated with inpatient mortality during daunorubicin and cytarabine induction in adults with acute myeloid leukemia-a national inpatient sample analysis.成人急性髓性白血病患者柔红霉素和阿糖胞苷诱导治疗期间住院死亡率的相关因素——一项全国住院患者样本分析
Ann Hematol. 2024 Feb;103(2):663-665. doi: 10.1007/s00277-023-05505-x. Epub 2023 Oct 27.
2
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.柔红霉素与伊达比星联合阿糖胞苷用于急性髓性白血病诱导治疗的疗效与安全性：一项随机临床试验的荟萃分析
Medicine (Baltimore). 2020 Jun 12;99(24):e20094. doi: 10.1097/MD.0000000000020094.
3
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.柔红霉素60与柔红霉素90及伊达比星12用于急性髓系白血病诱导化疗的回顾性分析：梅奥诊所经验
Haematologica. 2022 Oct 1;107(10):2474-2479. doi: 10.3324/haematol.2022.281045.
4
Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia.含中剂量阿糖胞苷诱导治疗在急性髓系白血病分子亚组中的获益
Haematologica. 2020 Sep 28;106(5):1491-1495. doi: 10.3324/haematol.2020.267526.
5
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.CPX-351（阿糖胞苷和柔红霉素）脂质体注射液与常规阿糖胞苷联合柔红霉素治疗新诊断的老年继发性急性髓系白血病患者的比较。
J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.
6
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.CPX-351 与 7+3 阿糖胞苷和柔红霉素化疗治疗新诊断的高危或继发性急性髓系白血病老年患者：一项随机、开放标签、多中心、3 期临床试验的 5 年结果。
Lancet Haematol. 2021 Jul;8(7):e481-e491. doi: 10.1016/S2352-3026(21)00134-4.
7
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.随机研究诱导治疗比较标准剂量伊达比星与高剂量柔红霉素在初治成人急性髓细胞白血病患者: JALSG AML201 研究。
Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6.
8
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.维奈克拉联合 3+7 方案的柔红霉素和阿糖胞苷化疗作为成人急性髓系白血病一线治疗：一项多中心、单臂、2 期临床试验。
Lancet Haematol. 2022 Jun;9(6):e415-e424. doi: 10.1016/S2352-3026(22)00106-5. Epub 2022 May 2.
9
Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.脂质体阿糖胞苷和柔红霉素（CPX-351）治疗老年急性髓系白血病患者。
Leuk Lymphoma. 2020 Jun;61(6):1305-1312. doi: 10.1080/10428194.2020.1719093. Epub 2020 Feb 8.
10
Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.维奈托克联合柔红霉素和阿糖胞苷进行“2+5”改良强化化疗用于适合的初治老年急性髓系白血病患者：一项单中心回顾性分析
Br J Haematol. 2023 May;201(3):568-572. doi: 10.1111/bjh.18709. Epub 2023 Mar 2.

本文引用的文献

1
Advances in acute myeloid leukemia.急性髓细胞白血病的研究进展。
BMJ. 2021 Oct 6;375:n2026. doi: 10.1136/bmj.n2026.
2
Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy.急性肾损伤会对接受诱导化疗的急性髓系白血病患者的临床病程产生不良影响。
Ann Hematol. 2021 May;100(5):1159-1167. doi: 10.1007/s00277-021-04482-3. Epub 2021 Mar 11.
3
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.
美国急性髓系白血病患者接受阿糖胞苷-蒽环类诱导化疗的治疗模式及临床结局
Blood Adv. 2020 Apr 28;4(8):1615-1623. doi: 10.1182/bloodadvances.2020001728.
4
Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).急性髓系白血病（AML）强化治疗的成年患者的合并症、年龄与死亡率。
J Geriatr Oncol. 2016 Jan;7(1):24-31. doi: 10.1016/j.jgo.2015.10.182. Epub 2015 Oct 30.
5
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.急性髓系白血病患者的高血糖与医院死亡率增加相关。
Cancer. 2007 Jul 1;110(1):96-102. doi: 10.1002/cncr.22777.
6
Effects of weekend admission and hospital teaching status on in-hospital mortality.周末入院及医院教学状况对院内死亡率的影响。
Am J Med. 2004 Aug 1;117(3):151-7. doi: 10.1016/j.amjmed.2004.02.035.